Anti-Mouse CD105 (Endoglin) – APC

Anti-Mouse CD105 (Endoglin) – APC

Product No.: C913

[product_table name="All Top" skus="C773"]

- -
- -
Clone
MJ7/18
Target
CD105
Formats AvailableView All
Product Type
Monoclonal Antibody
Alternate Names
Endoglin, Ancillary TGF-beta Receptor
Isotype
IgG2a κ
Applications
Agonist
,
Cell Sep - Pos
,
ELISA
,
FC
,
IF
,
IF Microscopy
,
IHC
,
IHC FF
,
IP
,
LCI
,
WB

- -
- -
Select Product Size
- -
- -

Antibody Details

Product Details

Reactive Species
Mouse
Host Species
Rat
Immunogen
Inflamed mouse skin
Product Concentration
0.2 mg/ml
Formulation
This Allophycocyanin (APC) conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.
Product Preparation
Functional grade preclinical antibodies are manufactured in an animal free facility using only in vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.
Pathogen Testing
To protect mouse colonies from infection by pathogens and to assure that experimental preclinical data is not affected by such pathogens, all of Leinco’s Purified Functional PLATINUM<sup>TM</sup> antibodies are tested and guaranteed to be negative for all pathogens in the IDEXX IMPACT I Mouse Profile.
Storage and Handling
This Allophycocyanin (APC) conjugate is stable when stored at 2-8°C. Do not freeze.
Country of Origin
USA
Excitation Laser
Red Laser (650 nm)
Applications and Recommended Usage?
Quality Tested by Leinco
FC2, 5, 11, 12, 13, 14,
WB2, 5, 6, 7,
ELISA6
Additional Applications Reported In Literature ?
IHC2, 4, 7, 8, 9, 10,
IHC FF19
IF5,
IF Microscopy6,
IP7,
Cell Sep-Pos12, 15,
Agonist14, 16,
LCI17, 18
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Description

Specificity
Anti-CD105 antibody (clone MJ7/18) activity is directed against mouse CD105 (endoglin).
Background
CD105 (endoglin) is a TGF-β superfamily co-receptor that promotes angiogenesis, is involved in endothelial integrin-mediated mural cell and leukocyte adhesion, antagonizes TGF-β mediated ERK activation, is essential to the immune response of macrophages, regulates trophoblast differentiation and invasion during pregnancy, promotes T-cell proliferation, and regulates differentiation and collagen expression in myofibroblasts1. CD105 is dysregulated in the vasculature of multiple diseases including cancer, preeclampsia, and hereditary hemorrhagic telangiectasia. Additionally, increased soluble CD105 is associated with numerous cardiovascular pathologies and metabolic disorders with some CD105 polymorphisms being associated with increased risk of cardiovascular damage. CD105 is an effective marker of the tumor vasculature and is a target for early cancer diagnosis and antiangiogenic therapies.

CD105 is alternatively spliced, resulting in both long (L-endoglin) and short (S-endoglin) forms1. The predominant isoform, L-endoglin, promotes the proliferation and migration of endothelial cells via enhanced ALK1-Smad1/5 signaling and is the presumed isoform when not specified in the literature. In contrast, S-endoglin enhances ALK5-Smad2/3 signaling. Endoglin has specific receptor-ligand interactions between type I and type II TGF-β superfamily receptors when binding TGF-β superfamily ligands. Mouse CD105 has three separate regions of similarity to TGF-β receptor III but does not contain the RGD tripeptide found in human CD1052.

MJ7/18 was produced by immunizing rats with inflamed mouse skin and selecting for reactivity with endothelial cells2, 3. MJ7/18 predominantly stains vascular endothelial cells and is a marker of mouse endothelium2, 4.

Antigen Details

Ligand/Receptor
TGF-ß1, TGF-ß3
PubMed
NCBI Gene Bank ID
Research Area
Immunology

References & Citations

1. Pawlak JB, Blobe GC. Dev Dyn. 251(1):137-163. 2022.
2. Ge AZ, Butcher EC. Gene. 138(1-2):201-206. 1994.
3. Berg EL, Goldstein LA, Jutila MA, et al. Immunol Rev. 108:5-18. 1989.
4. Hallmann R, Mayer DN, Berg EL, et al. Dev Dyn. 202(4):325-332. 1995.
5. Charbord P, Oostendorp R, Pang W, et al. Exp Hematol. 30(10):1202-1210. 2002.
6. Rivera LB, Brekken RA. J Cell Biol. 193(7):1305-1319. 2011.
7. Romero D, O'Neill C, Terzic A, et al. Cancer Res. 71(10):3482-3493. 2011.
8. Kruse A, Hallmann R, Butcher EC. Biol Reprod. 61(6):1393-1401. 1999.
9. Redaelli CA, Semela D, Carrick FE, et al. J Hepatol. 40(2):305-312. 2004.
10. Arguello AA, Fischer SJ, Schonborn JR, et al. Neuroscience. 159(3):1003-1010. 2009.
11. Izawa D, Tanaka T, Saito K, et al. Int Immunol. 11(12):1989-1998. 1999.
12. Lidington EA, Rao RM, Marelli-Berg FM, et al. Am J Physiol Cell Physiol. 282(1):C67-74. 2002.
13. Garton KJ, Gough PJ, Philalay J, et al. J Biol Chem. 278(39):37459-37464. 2003.
14. Kinderlerer AR, Pombo Gregoire I, Hamdulay SS, et al. Blood. 113(7):1598-1607. 2009.
15. Marelli-Berg FM, Peek E, Lidington EA, et al. J Immunol Methods. 244(1-2):205-215. 2000.
16. Ahmad SR, Lidington EA, Ohta R, et al. Immunology. 110(2):258-268. 2003.
17. Karmani L, Bouchat V, Bouzin C. Nanomedicine (Lond). 9(13):1923-1937. 2014.
18. Karmani L, Levêque P, Bouzin C, et al. Nucl Med Biol. 43(7):415-423. 2016.
19. Engelhardt B, Conley FK, Butcher EC. J Neuroimmunol. 51(2):199-208. 1994.
Agonist
Cell Sep - Pos
Indirect Elisa Protocol
Flow Cytometry
IF
IF Microscopy
IHC
IHC FF
Immunoprecipitation Protocol
LCI
General Western Blot Protocol

Certificate of Analysis

Disclaimer AlertProducts are for research use only. Not for use in diagnostic or therapeutic procedures.